# Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg

> **NCT00687973** · PHASE4 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 393 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Valsartan/amlodipine 80/5 mg tablets
- **DRUG:** Amlodipine 5 mg capsules
- **DRUG:** Amlodipine 10 mg capsules
- **DRUG:** Atenolol 50 mg tablets
- **DRUG:** Atenolol 100 mg tablets

## Key facts

- **NCT ID:** NCT00687973
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-01
- **Target enrollment:** 393 (ACTUAL)
- **Last updated:** 2011-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00687973

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00687973, "Effect of the Fixed Dose Combination Amlodipine/Valsartan on Central Aortic Blood Pressure in Uncontrolled Essential Hypertension With Amlodipine 5 mg". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00687973. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*